Search Results for 'placebo'

placebo published presentations and documents on DocSlides.

by cheryl-pisano

del carcinoma . della. . prostata. in . fase. ...

Pravastatin in Elderly Individuals at Risk of Vascular Dise

Pravastatin in Elderly Individuals at Risk of Vascular Dise

by phoebe-click

Presented at Late Breaking Clinical Trials. AHA 2...

EDUCATIONAL SLIDE MODULES

EDUCATIONAL SLIDE MODULES

by cheryl-pisano

Module D: . Evaluating CV safety and potential fo...

Long-Term Tolerability of

Long-Term Tolerability of

by briana-ranney

Ticagrelor. for Secondary Prevention: . Insights...

Kenneth W. Mahaffey, MD,

Kenneth W. Mahaffey, MD,

by myesha-ticknor

on behalf of the TRACER Investigators and Committ...

by lindy-dunigan

Understanding the mechanisms in the development o...

Tranexamic acid, civilian trauma and the CRASH-2 trial

Tranexamic acid, civilian trauma and the CRASH-2 trial

by sherrill-nordquist

Ian Roberts. Tranexamic acid and bleeding. The ...

Chapter 13 part 2

Chapter 13 part 2

by giovanna-bartolotta

Observational Studies and Experiments. Experiment...

by sherrill-nordquist

Head of Statistics for Internal Medicine RU . Ear...

The Safety and Tolerability of CSL112, a Reconstituted, Inf

The Safety and Tolerability of CSL112, a Reconstituted, Inf

by faustina-dinatale

A. poA. -I . E. vent reducin. G. in . I. schemic...

by aaron

W24. DCV + PR. Placebo + PR. Yes. Dore GJ. Gastro...

Pravastatin in Elderly Individuals at Risk of Vascular Dise

Pravastatin in Elderly Individuals at Risk of Vascular Dise

by min-jolicoeur

Presented at Late Breaking Clinical Trials. AHA 2...

Comparison of Adherence among Partners’ PrEP Participants on Placebo before and after Release of

Comparison of Adherence among Partners’ PrEP Participants on Placebo before and after Release of

by briana-ranney

B. Wamuti. , J. Odoyo, B. Rono, C. Cohen, E. Buku...

New Drug Update 2016 A Formulary Approach

New Drug Update 2016 A Formulary Approach

by test

J. Russell May, Pharm.D., FASHP. Clinical Profess...

Eating Behavior Defect: Consequences and New treatment Modalities

Eating Behavior Defect: Consequences and New treatment Modalities

by lois-ondreau

Charles SAAB MD / CEHP / MAACE . Consultant Endo...

Dabigatran in myocardial injury after noncardiac

Dabigatran in myocardial injury after noncardiac

by lois-ondreau

surgery. Dr. PJ Devereaux on behalf of . MANAGE I...

Medications for Obesity Management

Medications for Obesity Management

by aaron

Faisal . saeed. , MD.. Advocate weight Management...

Kenneth W. Mahaffey, MD,

Kenneth W. Mahaffey, MD,

by cheryl-pisano

on behalf of the TRACER Investigators and Committ...

1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery

1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery

by mitsue-stanley

Dr. PJ Devereaux on behalf of POISE. Investigato...

Presenters for Journal Club:

Presenters for Journal Club:

by alida-meadow

James Cooper. Eugenie . Shieh. Aaron . Schueneman...

Update on Treatment of Myasthenia Gravis

Update on Treatment of Myasthenia Gravis

by conchita-marotz

KUMC Neurology Grand Rounds. 07/29/2016. Richard...

How Do We Treat Obesity?

How Do We Treat Obesity?

by liane-varnes

Weight Loss Medications. 2. 3. Phentermine. 4. DE...

Planning for Retirement: Depression

Planning for Retirement: Depression

by debby-jeon

Richard C. Shelton, M.D.. James G. Blakemore Rese...

Asthma: A Highly Prevalent and Often Inadequately Controlled Disease

Asthma: A Highly Prevalent and Often Inadequately Controlled Disease

by lois-ondreau

1. Centers for Disease Control and Prevention (CD...

How Do We Treat Obesity?

How Do We Treat Obesity?

by karlyn-bohler

Weight Loss Medications. 2. 3. Phentermine. 4. DE...

UB Dept of Neurology UBMD Neurology/JNI

UB Dept of Neurology UBMD Neurology/JNI

by alida-meadow

brains. &GAINS. November 2, 2013. 9-12 a.m.. ...

CV safety & Outcome trials of

CV safety & Outcome trials of

by aaron

Oral . Antidiabetics. Adverse CV events led the F...

Trial Design Evolocumab SC

Trial Design Evolocumab SC

by danika-pritchard

140 mg Q2W or 420 mg QM. Placebo SC. Q2W or QM. L...

Apixaban vs VKA and

Apixaban vs VKA and

by cheryl-pisano

Apixaban vs VKA and Aspirin vs Placebo in Patie...

ETHICAL ASPECTS of

ETHICAL ASPECTS of

by cheryl-pisano

ETHICAL ASPECTS of PLACEBO SURGERY AAOS ETHICS ...

AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSIONS 2019

AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSIONS 2019

by yoshiko-marsland

AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSION...

PPAR  activation Clinical

PPAR  activation Clinical

by maniakti

evidence. Evolution of clinical evidence supportin...

Best of ASCO GU Session Sandy Srinivas.MD

Best of ASCO GU Session Sandy Srinivas.MD

by experimentgoogle

Stanford University. Outline. Abstract #4. :. . I...

Long -Term Efficacy of Dapagliflozin in T2DM Patients Receiving

Long -Term Efficacy of Dapagliflozin in T2DM Patients Receiving

by vamput

High-Dose Insulin. John . P.H. . Wilding, DM, FRCP...

Edward Fox, MD, PhD Phase 2 Multicenter Study Results of

Edward Fox, MD, PhD Phase 2 Multicenter Study Results of

by medmacr

Ublituximab. , a Novel Glycoengineered Anti-CD20 M...

Management of Dementia:

Management of Dementia:

by maniakiali

Pharmacologic and Non-Pharmacologic . Approaches. ...

EDUCATIONAL SLIDE MODULES

EDUCATIONAL SLIDE MODULES

by dsuser1

Module D: . Evaluating CV safety and potential for...

New Insights from EXSCEL

New Insights from EXSCEL

by pongre

M. Angelyn Bethel, MD. Associate Professor of Diab...

Submitter Name: Marta Ceko

Submitter Name: Marta Ceko

by jasmine

PI Name: Tor D. WagerPI email: tor.wager@colorado....

HIGHLIGHTSOFPRESCRIBINGINFORMATIONThesehighlightsdonotincludealltheinf

HIGHLIGHTSOFPRESCRIBINGINFORMATIONThesehighlightsdonotincludealltheinf

by byrne

Notforthereliefofacutebronchospasmorstatusasthmati...